NCT05091567: Phase 3: Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)
First Posted 2021-10-25 Trial status Active, not recruiting Sponsor Hoffmann-La Roche Abstract Presentation Meeting Abstract: 2025 ASCO Annual Meeting I May 28, 2025 Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Click here for details Peer-reviewed journal publication Efficacy and safety of first-line maintenance t
Dec 31, 2025
NCT04592913: Phase 3: (MATTERHORN): Neoadjuvant FLOT +/- Durvalumab Followed by Adjuvant FLOT +/- Durvalumab in GC/GEJC
First Posted 2020-10-19 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). Meeting Abstract: 2025 ASCO Annual Meeting II Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary June 04, 2025 Click here for det
Dec 31, 2025
NCT03036488: Phase 3: (KEYNOTE-522) Study of Pembrolizumab (MK-3475) Plus Chemo vs Placebo Plus Chemo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy
First Posted 2017-01-30 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation 2019 San Antonio Breast Cancer Symposium. Abstract GS3-03. Presented December 12, 2019. Schmid P, Park YH, Ferreira M, et al: KEYNOTE-522: Phase 3 study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo for early triple-negative breast cancer: Pathologic complete response in key subgroups and by treatm
Jun 29, 2021